Published in Eur J Pharmacol on May 19, 2000
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol (2007) 4.22
CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol (2010) 2.74
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Cannabinoid receptors and endocannabinoids: evidence for new players. AAPS J (2006) 2.01
Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol (2007) 2.01
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J (2007) 1.94
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology (2010) 1.82
Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol (2006) 1.77
Cannabinoid potentiation of glycine receptors contributes to cannabis-induced analgesia. Nat Chem Biol (2011) 1.70
Cannabinoids and neuroinflammation. Br J Pharmacol (2004) 1.62
Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain. Pain (2011) 1.60
The endocannabinoid system and pain. CNS Neurol Disord Drug Targets (2009) 1.59
Evaluation of the specificity of antibodies raised against cannabinoid receptor type 2 in the mouse retina. Naunyn Schmiedebergs Arch Pharmacol (2013) 1.58
Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J Neuroinflammation (2005) 1.57
Novel cannabinoid receptors. Br J Pharmacol (2007) 1.55
CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol (2007) 1.55
The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br J Pharmacol (2001) 1.49
Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol (2003) 1.47
The endocannabinoid system and cancer: therapeutic implication. Br J Pharmacol (2011) 1.46
Emerging role of the cannabinoid receptor CB2 in immune regulation: therapeutic prospects for neuroinflammation. Expert Rev Mol Med (2009) 1.44
Expression Analysis of CB2-GFP BAC Transgenic Mice. PLoS One (2015) 1.44
Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proc Natl Acad Sci U S A (2006) 1.41
Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics (2009) 1.36
Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain. J Neurosci (2008) 1.32
Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol (2006) 1.32
Species differences in cannabinoid receptor 2 (CNR2 gene): identification of novel human and rodent CB2 isoforms, differential tissue expression and regulation by cannabinoid receptor ligands. Genes Brain Behav (2009) 1.29
Endocannabinoid mechanisms of pain modulation. AAPS J (2006) 1.28
Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One (2008) 1.26
The peripheral cannabinoid receptor knockout mice: an update. Br J Pharmacol (2007) 1.25
Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One (2009) 1.25
CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol (2007) 1.24
Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol (2007) 1.21
Differential effects of two phospholipase D inhibitors, 1-butanol and N-acylethanolamine, on in vivo cytoskeletal organization and Arabidopsis seedling growth. Protoplasma (2005) 1.17
The antinociceptive effects of intraplantar injections of 2-arachidonoyl glycerol are mediated by cannabinoid CB2 receptors. Br J Pharmacol (2006) 1.16
Biology and therapeutic potential of cannabinoid CB2 receptor inverse agonists. Br J Pharmacol (2007) 1.15
Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proc Natl Acad Sci U S A (2014) 1.13
Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci (2008) 1.12
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia (2009) 1.11
Cannabinoids suppress inflammatory and neuropathic pain by targeting α3 glycine receptors. J Exp Med (2012) 1.11
Cannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated rats. Am J Physiol Gastrointest Liver Physiol (2008) 1.10
CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling. J Biol Chem (2011) 1.09
Validating Antibodies to the Cannabinoid CB2 Receptor: Antibody Sensitivity Is Not Evidence of Antibody Specificity. J Histochem Cytochem (2014) 1.09
Deletion of CB2 cannabinoid receptor induces schizophrenia-related behaviors in mice. Neuropsychopharmacology (2011) 1.07
Cannabinoids Delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem (2009) 1.07
Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain. J Neurosci (2008) 1.05
Formation of B and T cell subsets require the cannabinoid receptor CB2. Immunogenetics (2006) 1.05
Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol (2006) 1.05
Cannabinoid receptor 2 is critical for the homing and retention of marginal zone B lineage cells and for efficient T-independent immune responses. J Immunol (2011) 1.04
The endocannabinoid system and the regulation of neural development: potential implications in psychiatric disorders. Eur Arch Psychiatry Clin Neurosci (2009) 1.04
Cannabinoid receptors: nomenclature and pharmacological principles. Prog Neuropsychopharmacol Biol Psychiatry (2012) 1.03
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease. Br J Pharmacol (2011) 1.03
Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J Biol Chem (2009) 1.02
CNS effects of CB2 cannabinoid receptors: beyond neuro-immuno-cannabinoid activity. J Psychopharmacol (2011) 1.02
The plant cannabinoid Delta9-tetrahydrocannabivarin can decrease signs of inflammation and inflammatory pain in mice. Br J Pharmacol (2010) 1.01
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol (2007) 1.01
Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci (2012) 1.00
Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A (2010) 0.99
Expression and function of cannabinoid receptors CB1 and CB2 and their cognate cannabinoid ligands in murine embryonic stem cells. PLoS One (2007) 0.99
The evolution and comparative neurobiology of endocannabinoid signalling. Philos Trans R Soc Lond B Biol Sci (2012) 0.98
The cannabinoid delta-9-tetrahydrocannabinol mediates inhibition of macrophage chemotaxis to RANTES/CCL5: linkage to the CB2 receptor. J Neuroimmune Pharmacol (2007) 0.96
N-acylethanolamines are metabolized by lipoxygenase and amidohydrolase in competing pathways during cottonseed imbibition. Plant Physiol (2002) 0.96
Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown. Curr Med Chem (2010) 0.95
CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res (2011) 0.94
CB2 cannabinoid receptors contribute to bacterial invasion and mortality in polymicrobial sepsis. PLoS One (2009) 0.94
CB2 Cannabinoid receptors as a therapeutic target-what does the future hold? Mol Pharmacol (2014) 0.93
Inhibitory activity of the novel CB2 receptor agonist, GW833972A, on guinea-pig and human sensory nerve function in the airways. Br J Pharmacol (2008) 0.93
Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis. Am J Pathol (2010) 0.93
Cannabinoids as therapeutic agents for ablating neuroinflammatory disease. Endocr Metab Immune Disord Drug Targets (2008) 0.92
Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. Bioorg Med Chem (2007) 0.92
Signaling through cannabinoid receptor 2 suppresses murine dendritic cell migration by inhibiting matrix metalloproteinase 9 expression. Blood (2012) 0.91
Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol (2011) 0.91
Cannabinoid (CB2) receptor deficiency reduces the susceptibility of macrophages to oxidized LDL/oxysterol-induced apoptosis. J Lipid Res (2008) 0.90
Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS. Curr Neuropharmacol (2011) 0.90
Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol (2007) 0.90
Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system. Anesth Analg (2012) 0.89
The effects of targeted deletion of cannabinoid receptors CB1 and CB2 on intranasal sensitization and challenge with adjuvant-free ovalbumin. Toxicol Pathol (2010) 0.89
Anandamide and Delta9-tetrahydrocannabinol directly inhibit cells of the immune system via CB2 receptors. J Neuroimmunol (2007) 0.89
Diabetic retinopathy: Role of inflammation and potential therapies for anti-inflammation. World J Diabetes (2010) 0.88
Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation. AAPS J (2010) 0.87
Direct suppression of autoreactive lymphocytes in the central nervous system via the CB2 receptor. Br J Pharmacol (2007) 0.87
Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis (2010) 0.87
Deletion of cannabinoid receptors 1 and 2 exacerbates APC function to increase inflammation and cellular immunity during influenza infection. J Leukoc Biol (2011) 0.86
Targeting cannabinoid receptor CB(2) in cardiovascular disorders: promises and controversies. Br J Pharmacol (2012) 0.86
Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain. Anesth Analg (2010) 0.86
Retracted Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization. Blood (2010) 0.85
Interactions of the opioid and cannabinoid systems in reward: Insights from knockout studies. Front Pharmacol (2015) 0.85
Cannabinoid Receptor 2 Deficiency in Haematopoietic cells Aggravates Early Atherosclerosis in LDL Receptor Deficient Mice. Open Cardiovasc Med J (2011) 0.83
CB₂: therapeutic target-in-waiting. Prog Neuropsychopharmacol Biol Psychiatry (2011) 0.83
Cannabinoid 2 (CB2) receptor involvement in the down-regulation but not up-regulation of serum IgE levels in immunized mice. J Neuroimmune Pharmacol (2012) 0.83
Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma oncogenic herpesviruses in vitro. BMC Med (2004) 0.83
Effects of Cannabinoids on T-cell Function and Resistance to Infection. J Neuroimmune Pharmacol (2015) 0.82
What we know and do not know about the cannabinoid receptor 2 (CB2). Semin Immunol (2014) 0.81
Cannabinoid CB2 Receptors in a Mouse Model of Aβ Amyloidosis: Immunohistochemical Analysis and Suitability as a PET Biomarker of Neuroinflammation. PLoS One (2015) 0.81
Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis. PLoS One (2013) 0.81
Endogenous lipid activated G protein-coupled receptors: emerging structural features from crystallography and molecular dynamics simulations. Chem Phys Lipids (2013) 0.81
In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability. Prostaglandins Other Lipid Mediat (2009) 0.81
The transcriptional landscape of the mammalian genome. Science (2005) 37.63
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev (2002) 8.50
The ubiquitin pathway in Parkinson's disease. Nature (1998) 4.48
Genome-wide, large-scale production of mutant mice by ENU mutagenesis. Nat Genet (2000) 3.92
Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med (1998) 3.75
Hematopoietic cells differentiate into both microglia and macroglia in the brains of adult mice. Proc Natl Acad Sci U S A (1997) 3.59
Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc Natl Acad Sci U S A (1999) 3.54
Corticosteroid therapy of alcoholic hepatitis. Gastroenterology (1978) 3.21
Endothelial apoptosis in Braf-deficient mice. Nat Genet (1997) 2.77
Sequence interpretation. Functional annotation of mouse genome sequences. Science (2001) 2.54
Mice lacking the M3 muscarinic acetylcholine receptor are hypophagic and lean. Nature (2001) 2.39
Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J Neurosci (1997) 2.25
Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J Clin Invest (1996) 2.20
Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature (1996) 2.17
Sampling variability on percutaneous liver biopsy. Arch Intern Med (1979) 2.12
Cloning of a serotonin transporter affected by antidepressants. Science (1991) 2.12
Immunohistochemical signal amplification by catalyzed reporter deposition and its application in double immunostaining. J Histochem Cytochem (1996) 2.11
Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem (2000) 2.04
Aging and ethanol metabolism. Clin Pharmacol Ther (1977) 1.99
The expression pattern of a novel gene encoding brain-fatty acid binding protein correlates with neuronal and glial cell development. Development (1994) 1.98
Cholinergic dilation of cerebral blood vessels is abolished in M(5) muscarinic acetylcholine receptor knockout mice. Proc Natl Acad Sci U S A (2001) 1.87
Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia. Proc Natl Acad Sci U S A (2008) 1.86
Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem (2000) 1.78
Guidelines for the retention, storage, and use of residual dried blood spot samples after newborn screening analysis: statement of the Council of Regional Networks for Genetic Services. Biochem Mol Med (1996) 1.72
Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology (1993) 1.68
The human homologs of the raf (mil) oncogene are located on human chromosomes 3 and 4. Science (1984) 1.66
Mutations in SOD1 associated with amyotrophic lateral sclerosis cause novel protein interactions. Nat Genet (1997) 1.65
Cannabinoid receptors and their endogenous agonists. Annu Rev Pharmacol Toxicol (1998) 1.64
Quantitative in situ hybridization histochemistry reveals increased levels of corticotropin-releasing factor mRNA after adrenalectomy in rats. Neurosci Lett (1986) 1.62
Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. Pharmacol Biochem Behav (1993) 1.55
The endocannabinoid nervous system: unique opportunities for therapeutic intervention. Pharmacol Ther (2001) 1.53
TIP39: a new neuropeptide and PTH2-receptor agonist from hypothalamus. Nat Neurosci (1999) 1.49
Specificity and sensitivity of the assay for elastin-derived peptides in chronic obstructive pulmonary disease. Am Rev Respir Dis (1992) 1.48
Vasopressin and oxytocin mRNAs in adrenalectomized and Brattleboro rats: analysis by quantitative in situ hybridization histochemistry. Brain Res (1986) 1.47
More rapid elimination of alcohol in women as compared to their male siblings. Alcohol Clin Exp Res (1989) 1.47
Multileaf collimator interleaf transmission. Med Phys (1999) 1.44
Two receptors for vasoactive intestinal polypeptide with similar specificity and complementary distributions. Endocrinology (1994) 1.43
MouseBank: a database application for managing transgenic mouse breeding programs. Biotechniques (2001) 1.42
Stress and ethanol metabolism. Alcohol Alcohol (1998) 1.42
Trauma in cirrhosis: an indicator of the pattern of alcohol abuse in different societies. Alcohol Clin Exp Res (1991) 1.38
[Idiopathic facial palsy during pregnancy]. HNO (2012) 1.38
Quantitative histological analysis of the cerebellar nuclei in the cat. I. Numerical data on cells and on synapses. Exp Brain Res (1977) 1.37
Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am J Pathol (1999) 1.34
Intestinal malabsorption in folate-deficient alcoholics. Gastroenterology (1973) 1.33
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol (2010) 1.32
Characterization of murine A-raf, a new oncogene related to the v-raf oncogene. Mol Cell Biol (1986) 1.32
Gene-gene effects on central processing of aversive stimuli. Mol Psychiatry (2007) 1.32
Hypoalgesia in mice with a targeted deletion of the tachykinin 1 gene. Proc Natl Acad Sci U S A (1998) 1.31
Extrapituitary expression of the rat V1b vasopressin receptor gene. Proc Natl Acad Sci U S A (1995) 1.31
The dopamine receptor in adult and maturing kidney. Am J Physiol (1989) 1.31
Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci U S A (2005) 1.30
The patched signaling pathway in tumorigenesis and development: lessons from animal models. J Mol Med (Berl) (1999) 1.29
Expression of the CB1 and CB2 receptor messenger RNAs during embryonic development in the rat. Neuroscience (1998) 1.28
Effects of 6 weeks of therapy with oral doses of ICI 204,219, a leukotriene D4 receptor antagonist, in subjects with bronchial asthma. ACCOLATE Asthma Trialists Group. Am J Respir Crit Care Med (1994) 1.28
Transdifferentiation of rat hepatic stellate cells results in leptin expression. Biochem Biophys Res Commun (1998) 1.28
POU transcription factors control expression of CNS stem cell-specific genes. Development (1998) 1.28
A frequent ala 4 to val superoxide dismutase-1 mutation is associated with a rapidly progressive familial amyotrophic lateral sclerosis. Hum Mol Genet (1994) 1.27
Pro-opiomelanocortin-derived peptides (ACTH/beta-endorphin/alpha-MSH) in brainstem baroreceptor areas of the rat. Brain Res (1987) 1.24
Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab (1997) 1.24
CB2 receptors as new therapeutic targets for liver diseases. Br J Pharmacol (2007) 1.24
Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech Dev (2000) 1.23
Substance P receptor expression in intestinal epithelium in clostridium difficile toxin A enteritis in rats. Am J Physiol (1998) 1.21
Determination of [35S]guanosine-5'-O-(3-thio)triphosphate binding mediated by cholinergic muscarinic receptors in membranes from Chinese hamster ovary cells and rat striatum using an anti-G protein scintillation proximity assay. J Pharmacol Exp Ther (1999) 1.21
LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J Pharmacol Exp Ther (1998) 1.20
Embryonic expression of glial cell-line derived neurotrophic factor (GDNF) suggests multiple developmental roles in neural differentiation and epithelial-mesenchymal interactions. Mech Dev (1996) 1.20
Localization and dynamic regulation of biogenic amine transporters in the mammalian central nervous system. Front Neuroendocrinol (1998) 1.20
Midbrain serotonin transporter binding potential measured with [11C]DASB is affected by serotonin transporter genotype. J Neural Transm (Vienna) (2007) 1.19
Regulation of RAR beta 2 mRNA expression: evidence for an inhibitory peptide encoded in the 5'-untranslated region. J Cell Biol (1996) 1.18
Cannabinoid CB(1) receptor expression, activation and detection of endogenous ligand in trabecular meshwork and ciliary process tissues. Eur J Pharmacol (2001) 1.17
The upstream stimulatory factor binds to and activates the promoter of the rat class I alcohol dehydrogenase gene. J Biol Chem (1991) 1.17
Distribution of serotonin 5-HT1C receptor mRNA in adult rat brain. FEBS Lett (1989) 1.15
Cloning of the cocaine-sensitive bovine dopamine transporter. Proc Natl Acad Sci U S A (1991) 1.15
Dysregulated cannabinoid signaling disrupts uterine receptivity for embryo implantation. J Biol Chem (2001) 1.14
Pancreatic function and intestinal absorption in chronic alcoholism. Gastroenterology (1970) 1.14
Innervation of the nucleus of the solitary tract and the dorsal vagal nucleus by thyrotropin-releasing hormone-containing raphe neurons. Brain Res (1986) 1.14
Distribution of ethanol in the human gastrointestinal tract. Am J Clin Nutr (1973) 1.13
Corticotropin-releasing factor-immunoreactive neurons of the paraventricular nucleus become vasopressin positive after adrenalectomy. Proc Natl Acad Sci U S A (1984) 1.12
Single cell reverse transcription-polymerase chain reaction analysis of rat supraoptic magnocellular neurons: neuropeptide phenotypes and high voltage-gated calcium channel subtypes. Endocrinology (1999) 1.11
Identification of a GABAB receptor subunit, gb2, required for functional GABAB receptor activity. J Biol Chem (1999) 1.10
Praja1, a novel gene encoding a RING-H2 motif in mouse development. Oncogene (1997) 1.10
Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res (1990) 1.10
Sickle-cell disease not identified by newborn screening because of prior transfusion. J Pediatr (2000) 1.09
Craf-1 protein kinase is essential for mouse development. Mech Dev (1998) 1.09
Insulin growth factor I and hypogonadism in cirrhosis. Hepatology (2000) 1.08
Dexamethasone inhibits corticotropin-releasing factor gene expression in the rat paraventricular nucleus. Neuroendocrinology (1987) 1.08
Serotonin transporter messenger RNA in the developing rat brain: early expression in serotonergic neurons and transient expression in non-serotonergic neurons. Neuroscience (1998) 1.08
Activity of the beta-retinoic acid receptor promoter in transgenic mice. Mech Dev (1991) 1.08
Vitamin E and porphyrin metabolism in man. Arch Intern Med (1971) 1.08
[Pharmacokinetics and metabolism of trazodone in man (author's transl)]. Arzneimittelforschung (1976) 1.07
Meta-analysis of cannabinoid ligand binding affinity and receptor distribution: interspecies differences. Br J Pharmacol (2007) 1.07
Zafirlukast for symptomatic mild-to-moderate asthma: a 13-week multicenter study. The Zafirlukast Trialists Group. Clin Ther (1997) 1.06
Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertension (2000) 1.06
Sex difference in alcohol-related organ injury. Alcohol Clin Exp Res (2001) 1.06
M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system. Receptors Channels (2003) 1.05
Dispersed donor salivary gland cells are widely distributed in the recipient gland when infused up the ductal tree. Biotech Histochem (2009) 1.05